PHXM — Phaxiam Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €0.61m
- €12.08m
- €1.33m
Brief: Phaxiam Therapeutics Announces Judicial Liquidation And Delisting
Brief: Phaxiam Therapeutics Says Postponement Of The Offer Review Hearing
Brief: Phaxiam Therapeutics Announces Launch Of Process To Find Buyers In Context Of Its Receivership Procedure
Brief: Phaxiam Therapeutics Says Commercial Court Of Lyon To Open Judicial Receivership Procedure
Brief: PHAXIAM Provides Update On Deployment Of Strategy To Maximize Development Potential Of Phage Therapy
Brief: PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under The Compassionate Status In Europe
Brief: PHAXIAM Therapeutics FY Operating Expenses at EUR 25 Million
Brief: Phaxiam Therapeutics Announces Effective Delisting Of ADSs From Nasdaq
Brief: Phaxiam Announces Intention To Voluntary Delist American Depositary Shares From The Nasdaq Capital Market
Brief: Phaxiam Therapeutics And Vetophage Announce Strategic Research Collaboration
Brief: Phaxiam Therapeutics SA Says Net Loss For H1 2023 Was EUR 12.2 Mln, Compared With A Net Loss Of EUR 1 Mln For Same Period Of 2022
Brief: Phaxiam Therapeutics Announces A Reverse Share Split Of Its Shares
Brief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Erytech Pharma Says Akkadian Has Initiated New Legal Proceedings
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes
Brief: Erytech Says Pherecydes Will Be Merged Into Co
Brief: Erythech Pharma End-March Cash And Cash Equivalents Of EUR 30.5 Million